Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Nehal J. Lakhani, Jan Baughman et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 140
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory responseFernanda I. Arnaldez, Paolo A. Ascierto, Steven O’Day et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 93
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Clinical Cancer Research|2022Cited by 22
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Unknown|2023Cited by 0
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Unknown|2023Cited by 0